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Abstract
In 1977, Takatsuki and co-workers described in Japan a human malignant disease termed adult T-
cell leukemia (ATL). Three years later, in 1980, Gallo and colleagues reported the identification of
the first human retrovirus, human T-cell leukemia virus type I (HTLV-I), in a patient with cutaneous
T-cell lymphoma. This month, Retrovirology  commemorates these two land mark findings by
publishing separate personal recollections by Takatsuki and Gallo respectively on the discovery of
ATL and HTLV.
Retrovirology as a medical study first emerged in the early
1900s. In 1908, Ellermann and Bang reported on the
transmissibility of avian leucosis by cell-free filtrates, sug-
gesting the involvement of a virus [1]. Shortly afterward,
in 1910, Rous demonstrated that chicken sarcomas were
infectious and when inoculated into healthy birds
induced tumors [2]. Today, a plethora of oncogenic ani-
mal retroviruses including bovine leukemia virus, feline
leukemia virus, gibbon ape leukemia virus, Jaagsiektse
sheep retrovirus, murine leukemia virus, mouse mam-
mary tumor virus, reticuloendotheliosis virus, simian T-
cell lymphotropic virus, and Walleye dermal sarcoma
virus has been described.
Understanding how retroviruses cause cancer took a
major step forward with the development of the cellular
oncogene hypothesis in 1976. Thus Varmus, Bishop and
colleagues [3] demonstrated that the viral oncogenes (v-
onc) encoded by many retroviruses were captured origi-
nally from cellular sequences (i.e. c-onc). To date, three
general models of retroviral transformation are accepted:
a) over-expression of v-onc; b) cis-oncogenic effect from
promoter insertion; and c) cis-oncogenic effect from
enhancer insertion (Fig. 1A, B, C).
Although not yet fully understood, HTLV-I is believed to
transform human T-cells neither through the acquisition
of a c-onc  nor by cis-insertion effects on the cellular
genome. Pioneering molecular biology studies by Mit-
suaki Yoshida and colleagues led to the delineation of the
HTLV-I transforming gene, Tax [4]. Tax has no cellular
homologue; and it works in trans to disrupt cellular check-
points and destabilize genome integrity [5] leading to
transformation (Fig. 1D). A more extensive discussion of
the molecular biology of HTLV-I and its transforming
function will be in an upcoming comprehensive review by
Masao Matsuoka to be published in Retrovirology.
Two articles in this month's Retrovirology describe respec-
tively the discovery of adult T-cell leukemia [6] and HTLV-
I [7].
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Panels A, B, and C show the three accepted ways by which a retrovirus may transform cells: capture of a c-onc and over- expression of v-onc by the provirus (A); promoter insertion upstream of a growth controlling cellular gene (B); and enhancer  insertions either upstream of downstream of growth controlling cellular genes (C) Figure 1
Panels A, B, and C show the three accepted ways by which a retrovirus may transform cells: capture of a c-onc and over-
expression of v-onc by the provirus (A); promoter insertion upstream of a growth controlling cellular gene (B); and enhancer 
insertions either upstream or downstream of growth controlling cellular genes (C). Panel D shows the stepwise ways in which 
HTLV-I Tax oncoprotein may transform cells by i) inactivating checkpoints to induce tolerance of damaged DNA, and ii) per-
mitting the accumulation of unrepaired DNA lesions which ultimately convert a normal cell to a transformed cell.
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